Validation--how much can the world afford? Are we getting value for money?J Pharm Sci Technol. 1994 Jan-Feb; 48(1):45-8.JP
Abstract
The author raises questions not usually considered in discussions of validation: "How much validation can the world afford?," "Are we getting value for money?," and "What's in it for the patient?." The paper develops the theme that, while validation is undoubtedly important, the pharmaceutical industry has not given adequate thought as to whether the benefits of validation outweigh the costs in implementation of validation.
Links
MeSH
Pub Type(s)
Journal Article
Language
eng
PubMed ID
8004419
Citation
Anisfeld, M H.. "Validation--how Much Can the World Afford? Are We Getting Value for Money?" Journal of Pharmaceutical Science and Technology : the Official Journal of PDA, vol. 48, no. 1, 1994, pp. 45-8.
Anisfeld MH. Validation--how much can the world afford? Are we getting value for money? J Pharm Sci Technol. 1994;48(1):45-8.
Anisfeld, M. H. (1994). Validation--how much can the world afford? Are we getting value for money? Journal of Pharmaceutical Science and Technology : the Official Journal of PDA, 48(1), 45-8.
Anisfeld MH. Validation--how Much Can the World Afford? Are We Getting Value for Money. J Pharm Sci Technol. 1994 Jan-Feb;48(1):45-8. PubMed PMID: 8004419.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Validation--how much can the world afford? Are we getting value for money?
A1 - Anisfeld,M H,
PY - 1994/1/1/pubmed
PY - 1994/1/1/medline
PY - 1994/1/1/entrez
SP - 45
EP - 8
JF - Journal of pharmaceutical science and technology : the official journal of PDA
JO - J Pharm Sci Technol
VL - 48
IS - 1
N2 - The author raises questions not usually considered in discussions of validation: "How much validation can the world afford?," "Are we getting value for money?," and "What's in it for the patient?." The paper develops the theme that, while validation is undoubtedly important, the pharmaceutical industry has not given adequate thought as to whether the benefits of validation outweigh the costs in implementation of validation.
SN - 1076-397X
UR - https://www.unboundmedicine.com/medline/citation/8004419/Validation__how_much_can_the_world_afford_Are_we_getting_value_for_money
L2 - http://journal.pda.org/cgi/pmidlookup?view=long&pmid=8004419
DB - PRIME
DP - Unbound Medicine
ER -